Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Xinran Ma

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

X. Ma, N.C. Nussbaum, K. Magee, A.B. Bourla, M. Tucker, L. Bellomo, C. Bennette

Author affiliations

  • Quantitative Sciences, Research Oncology And Clinical Data, Flatiron Health, Inc., 10013 - New York City/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4442

Background

Real-world (rw) evidence derived from electronic health records (EHRs) is being explored for use as a comparator to single arm clinical trials in oncology. While RECIST is a standard for assessing tumor response in trials, alternative approaches are needed in rw cohorts. Our objective was to examine whether rwRR derived from abstracted “real-world tumor response” (rwTR) might perform similarly to RECIST-based response rates in a variety of settings to support assessments of drug efficacy.

Methods

We focused on randomized clinical trials supporting FDA approvals in aNSCLC between 2015-2017 (4 trials, 5 arms). We selected rw cohorts of aNSCLC patients from de-identified Flatiron Health EHR-derived database by applying the eligibility criteria of each trial as feasible, following an established internal process; trials were considered infeasible for comparison and not reported when fewer than 30 eligible rw patients were identified at the time of analyses. rwTR was abstracted from unstructured clinical notes and was based on the treating oncologist’s assessment of disease change (e.g., partial response) indicated by imaging at each point of radiographic disease evaluation. We compared the rwRRs observed in rw cohorts to objective response rates (ORRs) from trials.

Results

rw cohorts included 862 patients, and clinical trial cohorts (2 control arms and 3 experimental arms) included 701 patients, see response rates in the table (all except ALEX were confirmed RRs).Table:

1581P

TrialTrial armORRrwRR
CheckMate-017E: Nivolumab / 2L+ squamous20% (27/135)25% (17/68)
CheckMate-057E: Nivolumab / 2L+ nonsquamous19% (56/292)17% (51/294)
KEYNOTE-021E: Carboplatin, Pembrolizumab, Pemetrexed/ 1L nonsquamous55% (33/60)42% (37/88)
KEYNOTE-021C: Carboplatin and Pemetrexed/ 1L nonsquamous29% (18/63)34% (101/294)
ALEXC: Crizotinib/ 1L75% (114/151)68% (80/118)

Conclusions

Data curated from EHRs of rw patients with aNSCLC can provide estimates of response rates that are comparable to RECIST-based response rates observed in similar patient populations studied in clinical trial settings. These findings demonstrate the potential of leveraging rw cohorts as a comparator to single arm clinical trials in oncology.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Flatiron Health, Inc.

Funding

Flatiron Health Inc., independent subsidiary of the Roche group.

Disclosure

X. Ma: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. N.C. Nussbaum: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. K. Magee: Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. A.B. Bourla: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. M. Tucker: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. L. Bellomo: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche. C. Bennette: Shareholder / Stockholder / Stock options, Full / Part-time employment, Flatiron Health, Inc. is an independent subsidiary of the Roche Group.: Flatiron Health, Inc.; Shareholder / Stockholder / Stock options: Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.